Voyager Therapeutics, Inc.: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC amended its Schedule 13G filing on Voyager Therapeutics, Inc., disclosing a change to its passive stake in the gene therapy developer. The filing, submitted under SEC accession number 0001172661-26-005261, updates Armistice's previously reported beneficial ownership position. Schedule 13G amendments are typically filed when an investor's stake crosses or adjusts around the 5% threshold, though the filing summary did not specify the exact percentage or share count. The disclosure matters because Armistice is a notable institutional holder, and shifts in its position can signal changing sentiment toward Voyager's pipeline. Investors will watch for the specific ownership figures in the full filing and any subsequent 13F disclosures for confirmation of Armistice's current exposure.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Voyager Therapeutics, Inc.